Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods-Reference-Cited by-同舟云学术

Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods

Published:2021-06-07 Issue:12 Volume:35 Page:3600-3603
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Corre Jill^ORCID,Perrot Aurore^ORCID,Hulin Cyrille,Caillot Denis,Stoppa Anne-Marie,Facon Thierry,Leleu Xavier^ORCID,Dib Mamoun,Karlin Lionel,Moreau Philippe,Mohty Mohamad,Mariette Clara,Fontan Jean,Marolleau Jean-Pierre,Demarquette Hélène,Slama Borane,Voillat Laurent,Macro Margaret,Orsini-Piocelle Frédérique,Brechignac Sabine,Rey Philippe,Collet Philippe,Tiab Mourad,Belhadj Karim,Lifermann François,Clement-Filliatre Lauriane,Sohn Claudine,Richez Valentine,Avet-loiseau Hervé,

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-021-01250-0.pdf

Reference9 articles.

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.

2. Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104–15.

3. Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a Randomised, Open-Label, Phase 3 Trial. Lancet. 2020;395:132–41.

4. Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a Randomised, Open-Label, Phase 3 Study. Lancet. 2019;394:29–38.

5. Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132:2456–64.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Large-scale real-life analysis of survival and usage of therapies in multiple myeloma;Journal of Hematology & Oncology;2023-07-19

2. Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?;Pharmaceuticals;2023-04-14

3. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor;Blood;2023-03-16

4. Global real-life analysis of survival and usage of therapies in multiple myeloma;2023-02-23

5. How I approach smoldering multiple myeloma;Blood;2022-08-25